CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cellectis SA (ADR) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cellectis SA (ADR)
8 rue de la Croix Jarry
Phone: +33 181691600p:+33 181691600 PARIS, 75013  France Ticker: CLLSCLLS

Business Summary
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board Jean-PierreGarnier 75 11/1/2020 11/1/2020
Chief Executive Officer, Co-Founder, Director, Member of the Executive Board AndreChoulika 58 11/1/2020 1/1/2000
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Direc DavidSourdive 56 1/1/2021 1/1/2000
12 additional Officers and Directors records available in full report.

Business Names
Business Name
Calyxt, Inc.
Cellectis Biologics, Inc.
Cellectis, Inc.
CLLS

General Information
Number of Employees: 236 (As of 12/31/2022)
Outstanding Shares: 55,583,768 (As of 3/31/2023)
Stock Exchange: NASD
Fax Number: +33 181691606


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, September 27, 2023